Introduction in vitro . Rap1 is a member of the Ras superfamily of GTP-binding proteins that shares Elevation of intracellular cAMP produces growth effects 50% amino acid sequence identity with Ras (Kitayama in a variety of cell types, including inhibition of growth et al., 1990; Burgering and Bos, 1995) , and, like Ras, factor-stimulated cell growth in fibroblasts (Rat-1 and binds Raf isoforms in vitro and in vivo (Nassar et al., NIH 3T3 cells), smooth muscle cells, and adipocytes. 1996) . The GTP loading of Rap1 is stimulated by cAMP The ability of growth factors to stimulate cell proliferain vivo (Altschuler et al., 1995) . Although it is likely that tion requires the small G protein Ras and MAP kinase or GTP loading activates Rap1, in vivo effectors of Rap1 ERK (extracellular signal-regulated kinases) (Marshall, have not been defined. Instead, almost all of the actions 1995). Ras activates the serine/threonine kinases Raf-1 of Rap identified, to date, involve the inhibition of Rasand B-Raf (Lange-Carter et al., 1993; Vaillancourt et al., dependent signaling (Cook et al., 1993; Kitayama et al., 1994) , which, in turn, activate the MAP kinase kinase, 1990) . We show here that both PKA and Rap1 are selec-MEK, which then activates ERKs . It has tive activators of B-Raf in vivo and can activate selected been proposed that the inhibitory effects of cAMP on transcription factors and stimulate neuronal differencell growth reflect cAMP's inhibition of growth factor tiation via an ERK-dependent, but Ras-independent, activation of ERKs (Cook and McCormick, 1993; Wu et pathway. al., 1993) . In other cell types, including PC12 cells, cAMP does not antagonize the activation of ERKs by growth factors, but activates ERKs (Frodin et al., 1994; Young Results et al., 1994; Pan et al., 1995) and potentiates the effects of growth factors on differentiation and gene expression cAMP Induces Neuronal Differentiation via ERKs (Heidemann et al., 1985; Yao et al., 1995) .
cAMP's ability to differentiate PC12 cells was repro-PC12 cells are derived from rat adrenal medullary cells duced by transfection of the catalytic subunit of PKA and differentiate into sympathetic neurons upon treat-(cPKA) or treatment with the nonhydrolyzable cAMP anment with nerve growth factor (NGF) . alog 8-(4-chlorphenylthio)-cyclic AMP (8-CPT) ( Figure  1 ). Cells transfected with cPKA were identified by cotransfection with a cDNA encoding ␤-galactosidase (␤-gal). Cells transfected with ␤-gal and treated with these signals appear to activate ERKs via Ras-dependent mechanisms. Stimulation of myc-ERK2 by both 8-CPT or NGF developed neurites in 63% and 75% of ␤-gal ϩ cells, respectively (data not shown). These per-EGF and 8-CPT was completely blocked by expression of dominant-negative MEK-1 (MEK-K97R) ( Figure 2D ). centages were not affected by cotransfection of plasmid vector along with ␤-gal ( Figure 7I ). However, they were Therefore, like neuronal differentiation, cAMP's activation of MAP kinases requires MEK but is independent reduced by the expression of dominant-negative mutants of the ERKs (dnERK1 and dnERK2; dnERKs) (Fig- of Ras. ure 1B) and MKP-2 ( Figure 1C ), a MAP kinase phosphatase that is endogenously expressed in PC12 cells cAMP Activates Elk-1 via an ERK-Dependent, (Misra-Press et al., 1995) . The expression of the domiRas-Independent Mechanism nant-negative mutant of Ras (RasN17) also blocked the Elk-1, a member of the Ets family of transcription factors, ability of NGF ( Figure 1E ) to induce neurites but did not is an important physiological substrate of ERKs and block neurite outgrowth induced by 8-CPT ( Figure 1D ).
mediates serum-induced expression of immediate early genes (Marais et al., 1993) . The activation of ERKs was also assayed indirectly by measuring the transactivation cAMP's Activation of ERKs Is Independent of Ras of the 5ϫ Gal4-E1b/luciferase reporter gene by an Forskolin activated both ERK1 and ERK2 in PC12 cells Elk-1/Gal4 chimera (Misra-Press et al., 1995) . cAMP- (Figure 2A ). This action was selective; neither forskolin dependent Elk-1 activation was completely blocked by nor 8-CPT activated the related c-jun N-terminal kinases dnERKs, but not by interfering mutants of JNKs (Figure (JNKs) ( Figure 2B ). ERK2 activity was also stimulated 2E), despite the ability of these mutants to block activaby hormones and hormone analogs that are known tion of c-jun (data not shown). Therefore, Elk-1 activation activators of adenylyl cyclase, including vasoactiveis a useful measure of ERK activation by cAMP. Forskointestinal polypeptide (VIP) and isoproterenol (Figure lin's activation of Elk-1 was blocked by the PKA inhibitor 2C). ERK activation by these agents was inhibited by PKI, demonstrating the requirement for PKA ( Figure 2E ).
Forskolin's activation of Elk-1 was also blocked signifiline-sulfonamide), an inhibitor of PKA (Yao et al., 1995) , cantly by the expression of MEK-K97R but minimally by suggesting that PKA was required for these hormonal RasN17 ( Figure 2E ). As a control, we show that RasN17 actions, as well. Epitope-tagged ERK was used to examcan block activation of Elk-1 by NGF ( Figure 2E , right ine the effect of transfected mutants on ERK activity. panel). These data suggest that forskolin activates Elk-1, 8-CPT's activation of transfected myc-ERK2 was not as well as ERKs, at a level above MEK and downstream blocked by expression of Ras N17, while EGF's activaof, or parallel to, Ras. tion was blocked ( Figure 2D ). Basal ERK activation was also blocked by RasN17 to a similar degree as EGFstimulated ERK activity, suggesting that some constitucAMP Activates the Protein Kinase B-Raf Upstream activators of MEK include Raf-1 and B-Raf tive activation of upstream signaling cascades occurs under basal conditions. Like signals generated by EGF, (Moodie et al., 1994 . This assay was repeated three times with similar results. (E) Activation of ERK-dependent gene transcription by cAMP. PC12 cells were transfected with 10 g each of cDNAs encoding vector alone, dominant-negative JNK (dnJNK), dnERKs, PKI, MEK K97R, or RasN17, and treated with forskolin or left untreated, as indicated. In addition, all cells received 3 g of Elk-1/Gal4, 3 g of 5ϫ Gal4-E1b luciferase, and 3 g of CMV-CAT. Activation of Elk-1 is reflected by luciferase activity and was reported as fold activation above basal normalized for CAT activity. Standard error is indicated (n ϭ 3). The bar graph at right illustrates the requirement of Ras in NGF-mediated activation of Elk-1. Cells were transfected with vector or cDNA encoding RasN17 and treated with NGF. Luciferase assays of Elk-1 activity were performed as above. This serves as a control for the biological activity of the RasN17 cDNA.
B-Raf ( Figure 3A ) but, like forskolin, inhibited Raf-1 activvator of Elk-1 ( Figure 3D ). Forskolin's ability to activate Elk-1 also required transfection of B-Raf into these cells, ity (data not shown) (Vaillancourt et al., 1994 ). cAMP's regulation of Raf isoforms resulted in changes in Elk-1 and this ability increased with increasing doses of B-Raf. In contrast, forskolin inhibited the activation of Elk-1 by activation. Transfection of B-Raf into PC12 cells increased forskolin's activation of Elk-1. In contrast, forRaf-1, at all doses examined ( Figure 3E ). skolin's activation of Elk-1 was reduced following transfection of Raf-1 ( Figure 3B ). The actions of transfected Rap1 Activates B-Raf and ERKs In Vivo The mechanism by which cAMP induces Ras-indepen-B-Raf on cAMP signaling were more apparent in B-Rafdeficient cells. B-Raf is expressed primarily in neuronal dent activation of B-Raf is not known. The small G protein, Rap1, is activated by cAMP in vivo (Altschuler et and endocrine cells (Barnier et al., 1995) , and its expression was not detectable by immunoblot in NIH 3T3 fibroal., 1995) and has been shown to activate B-Raf in vitro . To ask whether B-Raf is a positive blasts ( Figure 3C ). B-Raf activity has been detected in NIH 3T3 cells by other techniques, suggesting that it is effector of Rap1 in vivo, we examined the actions of RapV12, a constitutively activated mutant of Rap1 in expressed, but at a much lower level than Raf-1 (Reuter et al., 1995) . To test the hypothesis that the expression which glycine at amino acid residue 12 is replaced with valine within the GTPase domain. Like in the analogous of B-Raf dictates cAMP's activation of MAP kinase, we introduced B-Raf into these cells. In the absence of Ras mutant, this results in increased GTP loading and a prolonged activation state (Kitayama et al., 1990) . In B-Raf, PKA was unable to activate Elk-1. However, transfection of B-Raf converted PKA into a potent acticontrast to its actions in other cell types, where it blocks were lysed, and transfected myc-ERK2 was immunoprecipitated with 9E10 antibody. Assays of myc-ERK activity were performed as (A) Activation of B-Raf by 8-CPT and EGF in PC12 cells. Cells were described in Figure 2 . Equal levels of myc-ERK expression were treated with 8-CPT or EGF, as indicated. B-Raf was immunoprecipiconfirmed by Western blot using antibody 9E10 (data not shown). tated and its activity measured in vitro using MEK-1 as a substrate.
The results of a representative experiment are shown with relative MEK-1 phosphorylation is indicated. The upper band corresponds kinase activities provided above. to autophosphorylation of B-Raf. This result is representative of (B) Requirement of MEK but not Ras for activation of Elk-1 by three independent experiments.
RapV12. PC12 cells were transfected with cDNAs encoding Elk-1/ (B) B-Raf and Raf-1 have opposing actions on forskolin-stimulated Gal-4 and 5ϫ Gal4-E1b/luciferase with 10 g of either vector, Elk-1 activity in PC12 cells. PC12 cells were transfected with plasRapV12, RasN17, or MEK-K97R, alone or in combination, as indimids encoding either B-Raf (10 g) or Raf-1 (10 g) and Elk-1/ cated. Luciferase activity was assayed as described in Figure 2E Gal-4 (3 g) and 5ϫ Gal4-E1b/luciferase (3 g) plasmids and were (n ϭ 3). subsequently treated with forskolin, as indicated. Elk-1 activation (C) Requirement of Rap for cAMP-dependent activation of Elk-1. was monitored by luciferase activity. Standard error is as shown PC12 cells were transfected with 3 g each of Elk-1/Gal4 and 5ϫ (n ϭ 3).
Gal4-E1b/luciferase and 5, 10, or 15 g of RapN17, as indicated. (C) B-Raf expression in PC12 cells and NIH 3T3 cells. B-Raf and Cells were treated with forskolin (n ϭ 6) or EGF (n ϭ 3) as indicated Raf-1 protein levels were determined by Western blot. 100 g of and luciferase assays performed as above. protein from whole cell lysates was analyzed by immunoblotting (D) Activation of Elk-1 by Rap1, cAMP, and B-Raf. PC12 cells were with B-Raf (left) and Raf-1 (right) antisera. Note that B-Raf was not transfected with plasmids encoding 10 g of either B-Raf, Rap1, detected in NIH 3T3 cells, and the 95 kDa form of B-Raf was the or RapV12 and 3 g of Elk-1/Gal-4 and 5ϫ Gal4-E1b/luciferase predominant form detected in PC12 cells. Raf-1 was expressed in plasmids, and subsequently treated with forskolin (1 M), as indiboth PC12 and NIH 3T3 cells.
cated. Elk-1 activation was monitored by luciferase activity (n ϭ 3). (D) Activation of Elk-1 in NIH 3T3 cells by cAMP following transfection of B-Raf. NIH 3T3 cells were transfected with plasmids encoding B-Raf (8 g) and/or cPKA (4 g), as indicated along with Elk-1-Gal-4 (5 g) and 5ϫ Gal4-E1b/luciferase (5 g) plasmids. Elk-1 actiRas-dependent activation of MAP kinase (Cook and vation was monitored by luciferase activity as in Figure 2E (n ϭ 3).
McCormick, 1993), RapV12 stimulates ERKs and Elk-1 (E) Opposing actions of B-Raf and Raf-1 on cAMP's regulation of in PC12 cells (Figures 4A and 4B) . These effects were Elk-1. NIH 3T3 cells were transfected with Elk-1/Gal4 and 5ϫ Gal4-not blocked by RasN17 but were blocked by MEK-K97R E1B luciferase as in (D). Cells were cotransfected with increasing ( Figures 4A and 4B) . Therefore, Rap1, like cAMP, actiamounts of B-Raf (left graph) or Raf-1 (right graph) and were either treated with forskolin or left untreated, as indicated.
vates the ERK cascade via a pathway that is independent of Ras but requires MEK. This action of RapV12 was selective for ERKs; it did not stimulate basal JNK activity or potentiate JNK activity stimulated by other agents (data not shown). These data confirm that Elk-1 activation by RapV12, like that of cAMP, is mediated by the ERK cascade.
Rap1 is phosphorylated by PKA at a single site, serine 179, within its carboxyl terminus (Altschuler and Lapetina, 1993) . A role of PKA in Rap1's activation of ERKs was suggested by the ability of RapD179 to activate ERKs in this assay ( Figure 4A ). RapD179 encodes a mutated Rap1 in which serine 179 was replaced with an aspartic acid residue to mimic phosphorylation at that position. Wild-type Rap1 had no effect in this assay (data not shown).
The requirement for Rap1 in cAMP's activation of Elk-1 was confirmed by using RapN17, a dominant-negative mutant corresponding to RasN17 (Stacy et al., 1991) . RapN17 blocked forskolin's activation of Elk-1 in PC12 cells. This inhibition was dose-dependent and specific; activation by EGF was not blocked at any dose ( Figure 4C ). These data demonstrate that endogenous Rap1 is necessary for forskolin's effects on Elk-1. Expression of exogenous Rap1 could potentiate forskolin's stimulation of Elk-1. In the absence of forskolin, wildtype Rap1 was unable to activate Elk-1, but in the presence of B-Raf and low doses of forskolin (1 M), Rap1 activated Elk-1 to levels greater than forskolin and B-Raf alone ( Figure 4D 
B-Raf Can Convert Rap1 into an Activator of Elk-1
To test the hypothesis that the expression of B-Raf permits RapV12, as well as PKA, to activate the MAP kinase cascade, we transfected NIH 3T3 cells with either B-Raf or Raf-1 and examined Elk-1 activation by RapV12. RapV12 activation of Elk-1 was greatly potentiated by cotransfecting B-Raf. The expression of B-Raf alone, in the absence of RapV12, had no effect on Elk-1. In contrast, Raf-1 activation of Elk-1 was completely blocked by RapV12 ( Figure 5D ). Therefore, like PKA, RapV12 selectively activates B-Raf in multiple cells. The small amount of activation of Elk-1 following transfection of RapV12 alone may reflect low endogenous levels of B-Raf in these cells (Reuter et al., 1995) or the presence of additional unidentified targets of Rap1. Altschuler et al., 1995) . In contrast, EGF had no effect prepared as described, and Rap1 was immunoprecipitated with or on GTP loading of Rap1 in these cells ( Figure 6B ). without antibody, as indicated. Immunoprecipitated proteins were resolved using 12% SDS-PAGE and visualized by autoradiography. ). This action of RapV12 was completely blocked by assay using B-Raf antisera. B-Raf activity associated MEK-K97R, but was only modestly blocked by RasN17 with His-Rap1 was greatly stimulated by PKA, to a level ( Figures 7D-7F ). Cotransfection of these mutants did similar to that associating with His-RapV12 ( Figure 6D , not alter the level of expression of transfected Rap proupper gel). The expression of equal amounts of His-Rap tein as confirmed by Western blotting (data not shown). was confirmed by immunoblotting with Rap1 antisera RapN17 ( Figures 7G and 7H ), but not vector control (data not shown). These data suggest that the associa-( Figure 7I ), interfered with the ability of 8-CPT, but not tion of activated B-Raf protein with Rap1 is increased NGF, to differentiate these cells. These data demonupon GTP loading, stimulated by PKA or by a V12 mustrate that Rap1 is required for cAMP-dependent differtation.
PKA Induces the Association of B-Raf
entiation of PC12 cells.
Constitutively Active Rap Stimulates Neuronal Discussion Differentiation in PC12 Cells
Transfection of RapV12, but not vector alone, induced
We demonstrate that B-Raf can convert cAMP into an activator of ERKs and Elk-1. The action of cAMP on neurite outgrowth in PC12 cells. The percentage of the 68 kDa. The majority of B-Raf expressed in those cells was a 68 kDa form, while only the minor 95 kDa form was shown to be activated by growth factors (LangeCarter et al., 1993; Vaillancourt et al., 1994) . In contrast, the PC12 cells used in this study express predominantly the 95 kDa form ( Figure 3C ). The inability of 68 kDa forms to be activated by growth factors may also account for the finding that cAMP's ability to activate ERKs does not correlate with the expression of the lower molecular weight forms of B-Raf (Faure and Bourne, 1995) .
cAMP Induces Activation of ERKs and Neuronal Differentiation via a Rap-Dependent, Ras-Independent Pathway
We show that cAMP's activation of ERKs, as well as the induction of neurite outgrowth by both cAMP and RapV12, is largely independent of Ras but requires Rap1. However, cells expressing both RapV12 and RasN17 showed decreased neurite length compared with RapV12 alone (Figure 7D ), suggesting that complete RapV12 (5 g) or RasV12 (5 g) and RSV-␤-gal (3 g) were cotransdifferentiation by Rap may require additional Rasfected into PC12 cells using lipofectamine (GIBCO/BRL). Transdependent pathways (Frech, et al., 1990) . vate Rap1 and ERKs via a Ras-independent mechanism may bypass this negative feedback loop regulating Rasdependent signaling, to permit cAMP to induce sus-B-Raf is the opposite of its action on Raf-1 (Wu et al., tained activation of ERKs associated with differentiation 1993; Burgering and Bos, 1995) . Unlike cAMP's inhibiin these cells. tion of growth factor activation of B-Raf, where cAMP blocks Ras-dependent pathways (Vaillancourt, et al., 1994 ), cAMP's activation of B-Raf utilizes the small G
Rap1 Is a Selective Activator of B-Raf
The specificity of cAMP for B-Raf is reflected in the protein Rap1. Rap1, like cAMP, activates B-Raf and inhibits Raf-1. Therefore, in cells that express B-Raf and actions of Rap1 on B-Raf. We demonstrate that Rap1 is a selective activator of B-Raf and that B-Raf can Raf-1, cAMP's actions on ERKs may represent a balance between its effects on each Raf isoform.
convert Rap1 and cAMP into activators of ERKs and Elk-1. In contrast, Ras can activate all known Raf isoforms. We show here that Rap1 activates B-Raf and cAMP Activates B-Raf in PC12 Cells and Transfected COS-7 Cells inhibits Raf-1. Therefore, despite its initial characterization as an antagonist of Ras, Rap1 may activate MAP Although cAMP can antagonize Ras-dependent activation of B-Raf, cAMP's regulation of B-Raf activity has kinase in B-Raf-expressing cells. This may explain the mitogenic effects of Rap1 in Swiss3T3 cells (Yoshida et not been examined independently of Ras activation (Vaillancourt et al., 1994; Erhardt et al., 1995) . We show al., 1992; Faure and Bourne, 1995) . The ability of B-Raf to convert inhibitory PKA signals into stimulatory ones that cAMP can activate B-Raf in PC12 cells in the absence of factors that activate Ras and that both cAMP may identify a novel role for B-Raf during development of hormonally responsive tissues. and PKA can stimulate B-Raf following transfection in COS-7 cells. This MEK kinase activity of B-Raf is limited
We show that the actions of cAMP on B-Raf are mediated by PKA's activation of Rap1. Both PKA activation to serines 218 and 222, sites responsible for the activation of MEK by Raf-1 (Alessi et al., 1994; Resing et al., and GTP loading of Rap1 induce the association of B-Raf with Rap1. It is possible that B-Raf may be activated by 1995). Therefore, PKA stimulates both the phosphorylation and activation of MEK via B-Raf. recruitment to membranes ( Figure 6C ) to form a complex with Rap1 in a manner similar to that shown for Raf-1 cAMP's activation of B-Raf and ERKs may depend on the cell lines examined. For example, one previous activation by Ras (Hallberg et al., 1994; Leevers et al., 1994; . In some cells, the ability to detect study was unable to detect activation of B-Raf or ERKs by cAMP (Vaillancourt et al., 1994) . The cells used in an association between endogenous Raf-1 and Ras proteins is limited, suggesting that the interaction between that study expressed two forms of B-Raf, 95 kDa and hr at 37ЊC in 5% CO2 prior to treatment with forskolin (10 mM), Raf-1 and Ras is transient (Leevers et al., 1994) . Differ-8-CPT (175 mM), NGF (100 ng/ml), EGF (50 ng/ml), VIP (10 mM), or ences in the activation of B-Raf and Raf-1 by Ras have isoproterenol (10 mM), unless otherwise indicated. been proposed (Yamamori et al., 1995; Jaiswal et al., 1996; Okada et al., 1996) . Therefore, the differences in Immune Complex Assays the ability to detect the association of endogenous Cells were grown to 50% confluence, serum-starved for 16 hr, and B-Raf with Rap1 and Ras may reflect biochemical differtreated with agents as indicated. ERK assays were performed using myelin basic protein (MBP) and [ 32 P]-␥ATP as substrates, as deences between the Raf isoforms, as well as differences scribed (Pan, et al., 1995) . JNK assays were performed using c-jun between Ras and Rap1 . and [ 32 P]P-␥ATP as substrates, as described (Dé rijard et al., 1994) .
The ability of RapN17 to inhibit cAMP's activation of For Raf assays, untreated and treated cells were lysed in 1% NP-40 B-Raf, ERKs, and differentiation in PC12 cells suggests buffer containing 10 mM Tris (pH 7.4), 5 mM EDTA, 50 mM NaCl, that a Rap-GEF may be required for each of these effects and 1 mM PMSF. Immune complex kinase assays were performed of cAMP (Stacy et al., 1991) . PKA increases the GTP as described, using MEK-1 and [
32 P]P-␥ATP as substrates (Vaillancourt et al., 1994) . The reaction products of all kinase assays were loading of Rap1 and phosphorylates Rap at a single site resolved by 10% SDS-polyacrylamide gel and analyzed with a Phos- (Altschuler and Lapetina, 1993; Altschuler et al., 1995) . Rap1. It has been previously shown that phosphorylation at this site may potentiate the actions of a Rap-
Construction of Expression Vectors
Wild-type Rap1b was cloned by PCR from a bovine brain cDNA specific GEF, Smg-GDS, in vitro (Hata et al., 1991) . The library, using specific primers to the published Rap1b sequence: requirement for this phosphorylation in Rap1 activation (sense oligo: GGCAAGCTTGAGACCATGCGTGAGTATAAGCTAGT in vivo has not been demonstrated, making it possible and antisense oligo: GGCGAATTCTATTAAAGCAGTGACATGAT that phosphorylation may lead to activation of Rap GACT), and subcloned into pcDNA3 (Invitrogen). RapV12 was conthrough other mechanisms and that PKA may have addistructed following PCR amplification of the full-length clone, using tional substrates to account for cAMP's activation of a mutant 5Ј oligonucleotide primer (sense oligo: GGCGGATCCATGC GTGAGTATAAGCTATCGTTCTTGGCTCTGTAGGCCTT) resulting in cell lysates were prepared and luciferase activity was assayed as Acknowledgments described (Misra-Press et al., 1995 (1993) . Mutational analysis of the above. Rap1 was precipitated with Ni-NTA-Agarose, and GTP loadcAMP-dependent protein kinase-mediated phosphorylation site of ing was assayed as described (Urano et al., 1996) F. (1993) . Inhibition by cAMP ras-depenwere homogenized, using a Dounce Homogenizer (Wheaton). Nuclei dent activation of raf. Science 262, 1069-1072. and cytoskeleton were pelleted by centrifugation at 5,000 rpm for Cook, S.J., Rubinfeld, B., Albert, I., and McCormick, F. (1993) . 10 min. The supernatant was collected and loaded on the top of RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 30% sucrose and spun at 100,000 ϫ g for 1 hr. The pellet was by LPA and EGF in Rat-1 fibroblasts. EMBO J. 12, 3475-3485. designated the membrane fraction. The membrane fraction was Cowley, S., Paterson, H., Kemp, P., and . Activaresuspended in solubilization buffer containing 1% NP-40, 10 mM tion of MAP kinase kinase is necessary and sufficient for PC12 Tris (pH 7.4), and protease inhibitors. The top 0.75 ml of the gradient differentiation and for transformation of NIH 3T3 cells. Cell 77, was collected as cytosolic proteins and was diluted with an equal 841-852. amount of 2ϫ membrane solubilization bufffer. Equivalent amounts of protein from treated and untreated cells were immunoprecipitated Dé rijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, with antisera against Rap1 as described above, resolved by 12% M., and Davis, R.J. (1994) . JNK1: a protein kinase stimulated by UV SDS-PAGE, and immunoblotted with antisera against B-Raf. Antilight and Ha-Ras that binds and phosphorylates the c-Jun activation body Y13-238 was used to immunopreciptate Ras from fractionated domain. Cell 76, 1025-1037. cells, as described above, and from unfractionated cells, as deErhardt, P., Troppmair, J., Rapp, U.R., and Cooper, G.M. (1995) . scribed (Warne et al., 1993) . B-Raf and Ras western blots were Differential regulation of Raf-1 and B-Raf and Ras-dependent activacarried out as described.
tion of mitogen-activated protein kinase by cyclic AMP in PC12 For studies in COS-7 cells, transfections were performed using cells. Mol. Cell. Biol. 15, 5524-5530. calcium phosphate. Cells were lysed in a buffer containing 1% Faure, M., and Bourne, H.R. (1995) . Differential effects of cAMP on NP-40, 10 mM Tris (pH 8.0), 20 mM NaCl, 30 mM MgCl2, 1 mM the MAP kinase cascade: evidence for a cAMP-insensitive step that PMSF, and 0.5 mg/ml aprotinin, and supernatants were prepared.
can bypass raf-1. Mol. Biol. Cell 6, 1025-1035. Transfected His-Rap proteins were precipitated from supernatants Frech, M., John, J., Pizon, V., Chardin, P., Tavitian, A., Clark, R., containing equal amounts of protein using Ni-NTA-Agarose, washed McCormick, F., and Wittinghofer, A. (1990) . Inhibition of GTPase with 20 mM imidazole in lysis buffer, and eluted with 500 mM imidaactivating protein stimulation of Ras-p21 GTPase by the Krev-1 gene zole, 5 mM EDTA in PBS. Eluates containing His-tagged proteins product. Science 246, 169-171. were separated on SDS-PAGE, and B-Raf protein was detected by Western blotting. Equal amounts of each eluate were immunopreFrodin, M., Peraldi, P., and Obberghen, E.V. (1994) . Cyclic AMP cipitated with B-Raf antisera, and B-Raf activity was measured by activates the mitogen-activated protein kinase cascade in PC12 immune complex assay. Equal amounts of Rap1 in each eluate were cells. J. Biol. Chem. 269, 6207-6214. confirmed by Western blotting.
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␤-Galactosidase Expression
Identification of Rap1 as a target for the Crk SH3 domain-binding PC12 cells were maintained in DMEM with 10% horse serum and guanine nucleotide--releasing factor C3G. Mol. Cell. Biol. 15, 6746-5% fetal calf serum on primaria (Falcon) plates. Plasmids encod-6753. ing ␤-galactosidase (3 mg/plate) and indicated plasmids were Hallberg, B., Rayter, S.I., and Downward, J. (1994) . Interaction of transfected using lipofectamine (GIBCO/BRL) in serum-free media, Ras and Raf in intact mammalian cells upon extracellular stimulation. stained for ␤-galactosidase activity as described (Yao et al., 1995) , J. Biol. Chem. 269, 3913-3916. and examined by light microscopy. The ratio of blue cells with and Hata, Y., Kaibuchi, K., Kawamura, S., Hiroyoshi, M., Shirataki, H., without neurites after transfection was compared to that in cells that and Takai, Y. (1991) . Enhancement of the actions of smg p21 GDP/ received vector and ␤-galactosidase alone, as described. Processes GTP exchange protein by the protein kinase A-catalyzed phosphorgreater than one cell body in length were counted as neurites.
ylation of smg p21. J. Biol. Chem. 266, 6571-6577. Greater than 200 blue cells were counted per condition, in three independent experiments.
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